هود التهوية من العوادم

معلومات اساسية

• متاح على:
• English
• العربية

Introducing the EarlyTect Colon Cancer Test, a groundbreaking diagnostic tool approved by the Korea Ministry of Food and Drug Safety. Developed through rigorous clinical trials conducted at esteemed medical facilities such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center, this test offers reliable results for individuals aged 30 to 80.

Using fecal DNA samples, the EarlyTect Colon Cancer Test has demonstrated an impressive 90% sensitivity and specificity in diagnosing colorectal cancer (CRC). By measuring the methylated Syndecan-2 biomarker, which is clinically associated with precancerous lesions of CRC, this qualitative real-time PCR test can effectively detect the presence of colorectal cancer.

It's important to note that while the EarlyTect Colon Cancer Test is highly accurate in identifying potential cases of CRC, it is not intended to provide a definitive diagnosis. A positive result indicates the possible presence of CRC or precancerous lesions of CRC, prompting further medical investigation.

Here are the product details:

- Cancer Type: Colorectal Cancer
- Target Population: Asymptomatic individuals seeking colorectal cancer screening
- Biomarker: SDC2 methylation

Please note that pricing and transaction conditions are subject to negotiation. To inquire about the EarlyTect Colon Cancer Test and request a quote, please contact us.